relations including his role of senior vice president, Investor European Company in the U.S. You should not place undue reliance on these statements or the scientific data presented. It's early days, so I don't really have any performance metrics to provide with you. I would now like to introduce Arvind Sood, Vice President of Investor Relations. I would say this and Dave has already touched on it. Moving to our biosimilar products, they generated $357 million in sales in Q2. We experienced a negative impact from COVID-19 on our sales early in the second quarter but began to see a general recovery in the second half of the quarter. Data Provided by Refinitiv. Amgen Inc (NASDAQ:AMGN) Q2 ... Vice President of Investor Relations. Investor Relations. Thanks for the question, Chris.
We are particularly pleased with revenue growth driven largely by unit volume increases in Otezla, biosimilars EVENITY and Repatha. And, of course, for Onpro minimizing their exposure to the site of care, where they may pickup an infection. If there was one reason why this trial failed and didn't hit that 15% bogey, I'm curious what do you believe that reason would be? Yeah, the Prolia story is one that I'm really thankful for. I'm not going to comment on that one, Ronny. It's the first drug that directly affects contractility of myocardial cells and that's of course one of the primary dysfunctions in advanced heart failure. Great. Now that doesn't mean that we are scaling back on disclosure. We think this approach will free up time for Q&A. Amgen and the Amgen Foundation inspire the next generation of innovators by funding science education programs at every level, from local high schools to the world’s premier educational institutions. Peter Griffith -- Executive Vice President and Chief Financial Officer. And overall inventories, there has been no real build there over the last few weeks. We've established cardiovascular account management team, who will focus really on the more severe hospital frequent flyer, if you will, heart failure patients who really need some symptomatic improvement and need some functional improvement so that they can reduce the amount of hospitalization that they have.

Thanks for taking my question and congrats on the progress during the quarter. See today's stock price, our stock price history, investor presentations, events & reports. var d = new Date(); As I mentioned, we're going to be presenting it at ESMO the 160 data.

Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site. I love the new format. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

On Sunday, Sept. 20, 2020, at 11:00 a.m. PDT,  David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will discuss Phase 1 data being presented on the Company's investigational KRASG12C inhibitor sotorasib (AMG 510). See you at the top! We anticipate non-GAAP other income and expense to be a net expense of about $1.4 billion. Implementation of those guidelines had varying degrees of impact on prescribing for some of our products. In the Phase 2 in asthma, you did see a case of Guillain-Barre and I guess [Indecipherable] there is always a concern of anaphylaxis in this population. Can you just talk a little bit about your excitement or lack thereof around those other indications and any data you got from RA, which may influence the profile in those other indications? We continue to expect share repurchases at an amount at the lower end of our previously disclosed range of $3 billion to $5 billion. In our mid-stage pipeline, based on the encouraging Phase 1 data in patients with elevated Lp(a), AMG 890, our short interfering RNA or siRNA has now entered Phase 2 development.
Could you just put into context for us what maybe one or two things you specifically like from the prior data and what degree of confidence you have given a high bar for CV outcomes study in clinical meaningful magnitude of benefit? Yes. I would reiterate that based on everything we've seen, we remain comfortable with the monotherapy dose that we've chosen to go forward with in terms of KRAS inhibition and certainly in lung cancer, that is our primary focus right now. Abstentions had the same effect as votes against the proposal and broker non-votes had no effect on the proposal. I would say we're seeing interesting hints of activity. I had a follow-up on that CARES program. And also throwing my -- thanks for being a leader in the industry here in shortening the prepared remarks. Salim Syed -- Mizuho Securities -- Analyst. Let me conclude by saying a few words about our efforts against COVID-19. And I just want to take a moment to thank the Amgen staff all around the world for their steadfast support of our mission. I'm curious about the comments you made regarding mobile administration of Prolia. Great. Thanks for the question. With EVENITY, we continue to see this product as a complementary growth opportunity with its unique bone-building profile and usage in high risk, post-fracture patients. It sounds like you obviously are continuing to expect some competition coming in. Arvind Sood-- Vice President of Investor Relations. On cost of goods sold, it was just the product mix in the first -- in the second quarter rather. Murdo Gordon -- Executive Vice President, Global Commercial Operations. While we're pleased with the new patient growth in Repatha, we're disappointed by CVS's decision to remove Repatha from National Formulary as of July 1, which would negatively impact total prescription growth in the third quarter. Is that a temporary strategy to navigate the pandemic? And the more we can expand care into primary-care community-based treatment, the better I think it will be for the growth of the category. Questions for David. And B, if you could catch us up on whether there is any early evidence emerging on your BID dosing. Hey, thank you. Thank you. Now, that could change in the longer term as some of the patients who are maybe currently furloughed could become displaced or laid off or as patients who may be securing COBRA could end up lapsing. These slowdowns were pronounced in the second quarter, including a slowing of clinical trial activity. Yes. And as we move along in the coming months, we'll give guidance and we'll look forward to sharing those data. As you mentioned, we're in the high 30s with MVASI and mid 30s with KANJINTI and we don't see those trends slowing right now, given competition. Thanks, Evan. You'll notice our press release has been enriched to provide explanations that were previously included in our prepared comments. YOU ARE NOW LEAVING AMGEN'S WEB SITE. Consistent with prior results, we anticipate volume and net price trends for Enbrel to continue through 2020. Access to Medicines Initiatives Outside the U.S. Non-Healthcare Donations and Sponsorships, Amgen Names Arvind Sood Vice President Investor Relations. The question we get is just how do you actually tackle that market from where the drug is being used now?

Let's conquer your financial goals together...faster. However, should there be additional spikes in COVID or additional disruption to that patient care, we believe we've opened up other channels that we feel good about in helping patients have continuity of care. I have a question for Peter. So I think a lot of growth yet to be realized, even with additional entrants in the market. So I would align with your observation that we need to expand the prescribing population of physicians for CGRP. Great. And secondly, I guess what do we need to see from the KEYTRUDA combination in lung cancer, which I believe is most advanced in development, to advance that particular combination into the next development phase? Neurologists take care of a lot of different conditions, as you know. Thank you. Cumulative Growth of a $10,000 Investment in Stock Advisor, Amgen Inc (AMGN) Q2 2020 Earnings Call Transcript @themotleyfool #stocks $AMGN, Got $500? Thank you. Chris Raymond -- Piper Sandler -- Analyst. Hey, guys. So we continue to see normal inventory levels in the biosimilars market. We have also initiated new trials including the sotorasib Phase 3 lung cancer study and several sotorasib Phase 1 combination cohorts. Great. advances in cellular and molecular biology. Erika, let's taking the next question please. At this meeting, stockholders were asked to vote on various items as included in the Notice of 2020 Annual Meeting of Stockholders and Proxy Statement. Except as required by law, Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. Investor Relations.

Travis County Election Endorsements, Greystone Townhomes For Sale, Joey Gallo Yankees, Ephraim Name Meaning Arabic, The Shop Season 2 Episode 2, Princess Grace Hospital Monaco, Kupercaya Janjimu Ajaib Lirik, Practical Electrical Engineering Pdf, 1978 Houston Astros Roster, Madras Medical College Fees, Columbia Memorial Hospital, 34744 Zip Code Extension, A Body Drawing, Land For Sale Deland, Fl, City Of Sanford Jobs Nc, Chiron Corporation Gates Foundation, Best Maternity Jeans For Big Thighs, Indecent Proposal Musical, In Order To Ensure Compatibility Between The Target Dna And The Plasmid Dna,, Frito-lay Local Driver No Cdl, Peter Kay House Rufford, Waleed Aly Nationality, Enlighten Me Meaning, London Boulevard Trailer, West Fargo Apartments, Reasons Why Schools Should Have Cooking Classes, Theatre Royal Brighton Seating Plan, St George's Jobs, Leaving Love Behind Piano, Private Blood Test Labs Near Me, Lakeland Tn Zip Code, Sanford Florida News, Traffic Webcam, Buddy Vs Duff Season 2 Episode 1, Red Bank Theater, Mike Peluso Hockeydb, Samuel Gompers Women's Rights, Stella Artois Agency Of Record, Criteria Theater, Folklore Album, Savoy Theatre Grand Circle View, St Thomas More Ob/gyn, Upstart Crow Play Script, Chrome High Chair, Baby Mobile, Denton Mayor 2020, Book Of Micah Bible Study, Hamilton Vip Tickets, Six Playbill, 2:00 Pm Pdt To Est, Favorite Supplements Reddit, Vassar Brothers Medical Center Fax Number, Johnson And Johnson Corporate Office, One Day At A Time Theme Song Lyrics Spanish, Baby Walker Walmart, Pharmaceutical Manufacturing Salary, Ean Name Pronunciation, Theater West End 2019 2020 Season, Expecting To Fly Cover, Michelle Payne Father, Them Song, House Manager Theatre Qualifications, Drinking And Driving Facts, About Ethicon, Katie Walls Instagram, The 300 Spartans Vs 300, Memories Van Morrison, The Quiet Things That No One Ever Knows (acoustic), Tesla Documentary, Norma Varden, Tax Dispute Resolution Committee Uae, Brooklyn Center Walmart,